Risk factor
Low price volatility
Profitability factor
Very low or no dividends
About
Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada, Latin America, and internationally. It offers Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib to treat metastatic cholangiocarcinoma; Trelstar...
Company Valuation
From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. In particular, the stock is overpriced on P/E, of fair value on EV/
Target Price
The average target price of GUD.TO is 8.4 and suggests 43% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre
Buy
Sell